Business
Shareholders that lost money on Capricor Therapeutics should contact Faruqi & Faruqi about pending Class Action - CAPR
If You Suffered Losses Exceeding $50,000 in Capricor between October 9, 2024 and July 10, 2...
About this update from Caprock Mining Corp
[{"type":"text","content":"Shareholders that lost money on Capricor Therapeutics should contact Faruqi & Faruqi about pending Class Action - CAPRIf You Suffered Losses Exceeding $50,000 in Capricor between October 9, 2024 and July 10, 2025 Securities Litigation Partner James (Josh) Wilson Encourages you to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here to find out if you qualify for the class action]New York, New York--(Newsfile Corp. - August 26, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (\"Capricor\" or the \"Company\") (NASDAQ: CAPR) and reminds investors of the September 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that defendants provided investors with material information concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application.Following this news, the ...